Company Information

History

Phynova commenced trading at the Oxford Science Park in July 2002.  The company’s initial focus was the development of new pharmaceuticals for Western markets utilising a novel drug discovery model derived from medicinal plants used in TCM. The Company's headquarters are now located in Blenheim Office Park in Oxford.

In 2008, the company broadened its focus to include the development of natural functional ingredients for the food, healthcare and personal care industries. In 2009, Phynova began the development and registration of several new OTC drugs that conform to the EU’s Traditional Medicinal Herbal Products (THMP) Directive. 

Since its founding in 2002, Phynova has raised total equity of £11 million, which has been used to develop a product portfolio that includes:

  • New drug candidates for chronic hepatitis C (CHC), postoperative ileus (POI) and antibiotic-resistant bacteria, viz. methicillin-resistant Staphylococcus aureus (MRSA)

  • Functional ingredients for fatigue, liver health and moderating blood glucose levels

  • A cosmetic ingredient for skin lightening

  • Several TCM derived OTC drug candidates for the relief of arthritis, colds and flu and other indications.


In 2006, Phynova acquired a 45 percent stake in Botanic Century Company Limited (BCCL), a Beijing based botanical drug development company. The founders hold the remaining 55 percent. BCCL’s management and staff are highly skilled scientists with extensive experience in the development of plant-derived drugs and functional ingredients.